<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37208665</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>22</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>22</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1546-0096</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>May</Month><Day>19</Day></PubDate></JournalIssue><Title>Pediatric rheumatology online journal</Title><ISOAbbreviation>Pediatr Rheumatol Online J</ISOAbbreviation></Journal><ArticleTitle>Aquaporin-4 IgG antibodies: predictors of positivity and their relationship with neuropsychiatric disorders and white matter lesions in Juvenile systemic lupus erythematosus.</ArticleTitle><Pagination><StartPage>47</StartPage><MedlinePgn>47</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">47</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12969-023-00827-6</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">This study aimed to describe the prevalence of the various clinical features and severity of juvenile systemic lupus erythematosus (jSLE) and to assess predictors of AQP4-Ab positivity in jSLE. In addition, we assessed the relationship of AQP4-Abs with neuropsychiatric disorders and white matter lesions in jSLE.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">For 90 patients with jSLE, demographic data, clinical manifestations, and treatments received were recorded, and all of the patients were underwent clinical examinations, including assessments for the neurological manifestations of jSLE and neuropsychiatric disorders; Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score evaluations; laboratory investigations, including serum AQP4-Ab assays; and 1.5 Tesla brain MRI. Echocardiography and renal biopsy were performed for the indicated patients.</AbstractText><AbstractText Label="RESULT" NlmCategory="RESULTS">Fifty-six patients (62.2%) tested positive for AQP4-Abs. These patients were more likely to have higher disease activity scores (p&#x2009;&lt;&#x2009;0.001); discoid lesions (p&#x2009;=&#x2009;0.039); neurological disorders (p&#x2009;=&#x2009;0.001), mainly psychosis and seizures (p&#x2009;=&#x2009;0.009 and p&#x2009;=&#x2009;0.032, respectively); renal and cardiac involvement (p&#x2009;=&#x2009;0.004 and p&#x2009;=&#x2009;0.013, respectively); lower C3 levels (p&#x2009;=&#x2009;0.006); white matter hyperintensities (p&#x2009;=&#x2009;0.008); and white matter atrophy (p&#x2009;=&#x2009;0.03) than patients who were negative for AQP4-Abs. Furthermore, AQP4-Ab-positive patients were more likely to have received cyclophosphamide (p&#x2009;=&#x2009;0.028), antiepileptic drugs (p&#x2009;=&#x2009;0.032) and plasma exchange therapy (p&#x2009;=&#x2009;0.049).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">jSLE patients with higher severity scores, neurological disorders, or white matter lesions could develop antibodies against AQP4. We recommend more studies for systematic screening of AQP4-Ab positivity in jSLE patients to confirm its relationship with neurological disorders.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shaaban</LastName><ForeName>Yasmeen</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Paediatrics, Mansoura University Children's Hospital, Mansoura, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>El-Marsafawy</LastName><ForeName>Hala</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Paediatrics, Mansoura University Children's Hospital, Mansoura, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>El-Farahaty</LastName><ForeName>Reham M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Department of Clinical Pathology, Faculty of Medicine, Mansoura University, Mansoura, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>El-Ziny</LastName><ForeName>Sherine</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Mansoura University, Mansoura, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>El-Refaey</LastName><ForeName>Ahmed M</ForeName><Initials>AM</Initials><Identifier Source="ORCID">0000-0002-1055-7131</Identifier><AffiliationInfo><Affiliation>Department of Paediatrics, Mansoura University Children's Hospital, Mansoura, Egypt. arefaey72@mans.edu.eg.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Pediatr Rheumatol Online J</MedlineTA><NlmUniqueID>101248897</NlmUniqueID><ISSNLinking>1546-0096</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051401">Aquaporin 4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051401" MajorTopicYN="N">Aquaporin 4</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066127" MajorTopicYN="Y">White Matter</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012640" MajorTopicYN="N">Seizures</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014652" MajorTopicYN="Y">Vascular Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">AQP4-Ab</Keyword><Keyword MajorTopicYN="N">Aquaporin</Keyword><Keyword MajorTopicYN="N">Neuromyelitis optica spectrum disorders (NMOSDs)</Keyword><Keyword MajorTopicYN="N">White matter lesions</Keyword><Keyword MajorTopicYN="N">jSLE</Keyword></KeywordList><CoiStatement>The authors declared no potential conflicts of interest concerning the research, authorship, and/or publication of this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>22</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>20</Day><Hour>9</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>19</Day><Hour>23</Hour><Minute>35</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37208665</ArticleId><ArticleId IdType="pmc">PMC10197312</ArticleId><ArticleId IdType="doi">10.1186/s12969-023-00827-6</ArticleId><ArticleId IdType="pii">10.1186/s12969-023-00827-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hedrich CM, Smith EM. Beresford MWJBp, rheumatology rC. Juvenile-onset systemic lupus erythematosus (jSLE)&#x2013;Pathophysiological concepts and treatment options. 2017;31(4):488&#x2013;504.</Citation><ArticleIdList><ArticleId IdType="pubmed">29773269</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahin S, Adrovic A, Barut K, Canpolat N, Ozluk Y, Kilicaslan I, et al. Juvenile systemic lupus erythematosus in Turkey: demographic, clinical and laboratory features with disease activity and outcome. Lupus. 2018;27(3):514&#x2013;9. doi: 10.1177/0961203317747717.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203317747717</ArticleId><ArticleId IdType="pubmed">29233038</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdwani R, Abdalla E, Al-Zakwani I. Unique characteristics of prepubertal onset systemic lupus erythematosus. International journal of pediatrics. 2019;2019.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6556776</ArticleId><ArticleId IdType="pubmed">31263503</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdel-Hafez M, Abdel-Nabi H. Juvenile systemic lupus erythematosus: onset patterns and short-term outcome in egyptian children, a single-center experience. Lupus. 2015;24(13):1455&#x2013;61. doi: 10.1177/0961203315598016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203315598016</ArticleId><ArticleId IdType="pubmed">26223297</ArticleId></ArticleIdList></Reference><Reference><Citation>El Hadidi K, Medhat B, Abdel Baki N, Abdel Kafy H, Abdelrahaman W, Yousri A, et al. Characteristics of systemic lupus erythematosus in a sample of the egyptian population: a retrospective cohort of 1109 patients from a single center. Lupus. 2018;27(6):1030&#x2013;8. doi: 10.1177/0961203317751856.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203317751856</ArticleId><ArticleId IdType="pubmed">29431056</ArticleId></ArticleIdList></Reference><Reference><Citation>Sibbitt WL Jr, Brooks WM, Kornfeld M, Hart BL, Bankhurst AD, Roldan CA, editors. Magnetic resonance imaging and brain histopathology in neuropsychiatric systemic lupus erythematosus. Seminars in arthritis and rheumatism. Elsevier; 2010.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3586567</ArticleId><ArticleId IdType="pubmed">19880162</ArticleId></ArticleIdList></Reference><Reference><Citation>Papadopoulos MC, Verkman AS. Aquaporin water channels in the nervous system. Nat Rev Neurosci. 2013;14(4):265&#x2013;77. doi: 10.1038/nrn3468.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn3468</ArticleId><ArticleId IdType="pmc">PMC3732112</ArticleId><ArticleId IdType="pubmed">23481483</ArticleId></ArticleIdList></Reference><Reference><Citation>Hinson SR, Lennon VA, Pittock SJ. Autoimmune AQP4 channelopathies and neuromyelitis optica spectrum disorders. Handb Clin Neurol. 2016;133:377&#x2013;403. doi: 10.1016/B978-0-444-63432-0.00021-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/B978-0-444-63432-0.00021-9</ArticleId><ArticleId IdType="pubmed">27112688</ArticleId></ArticleIdList></Reference><Reference><Citation>Moraitis E, Stathopoulos Y, Hong Y, Al-Obaidi M, Mankad K, Hacohen Y, et al. Aquaporin-4 IgG antibody-related disorders in patients with juvenile systemic lupus erythematosus. Lupus. 2019;28(10):1243&#x2013;9. doi: 10.1177/0961203319855125.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203319855125</ArticleId><ArticleId IdType="pubmed">31213132</ArticleId></ArticleIdList></Reference><Reference><Citation>Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Arthritis &amp; rheumatology. 2019;71(9):1400&#x2013;12. doi: 10.1002/art.40930.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.40930</ArticleId><ArticleId IdType="pmc">PMC6827566</ArticleId><ArticleId IdType="pubmed">31385462</ArticleId></ArticleIdList></Reference><Reference><Citation>Khajezadeh M-A, Zamani G, Moazzami B, Nagahi Z, Mousavi-Torshizi M, Ziaee V. Neuropsychiatric involvement in juvenile-onset systemic lupus erythematosus. Neurology research international. 2018;2018.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5996412</ArticleId><ArticleId IdType="pubmed">30002929</ArticleId></ArticleIdList></Reference><Reference><Citation>Abrahamowicz M, Fortin PR, du Berger R, Nayak V, Neville C, Liang MH. The relationship between disease activity and expert physician&#x2019;s decision to start major treatment in active systemic lupus erythematosus: a decision aid for development of entry criteria for clinical trials. J Rhuematol. 1998;25(2):277&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">9489819</ArticleId></ArticleIdList></Reference><Reference><Citation>Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rhuematol. 2002;29(2):288&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">11838846</ArticleId></ArticleIdList></Reference><Reference><Citation>Asgari N, Jarius S, Laustrup H, Skejoe HP, Lillevang ST, Weinshenker BG, et al. Aquaporin-4-autoimmunity in patients with systemic lupus erythematosus: a predominantly population-based study. Multiple Scler J. 2018;24(3):331&#x2013;9. doi: 10.1177/1352458517699791.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1352458517699791</ArticleId><ArticleId IdType="pubmed">28326889</ArticleId></ArticleIdList></Reference><Reference><Citation>Bundhun PK, Kumari A, Huang F. Differences in clinical features observed between childhood-onset versus adult-onset systemic lupus erythematosus: a systematic review and meta-analysis. Medicine. 2017;96(37).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5604682</ArticleId><ArticleId IdType="pubmed">28906413</ArticleId></ArticleIdList></Reference><Reference><Citation>Ale&#x2019;ed AA, Al-Mayouf SM. Systemic lupus erythematosus in arab children. Differences and similarities with different ethnicities. Saudi Med J. 2014;35(6):566&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">24888655</ArticleId></ArticleIdList></Reference><Reference><Citation>Torrente-Segarra V, TC SM, R&#xfa;a-Figueroa I, S&#xe1;nchez-Alonso F, L&#xf3;pez-Longo FJ, Galindo-Izquierdo M, et al. Juvenile-and adult-onset systemic lupus erythematosus: a comparative study in a large cohort from the Spanish Society of Rheumatology Lupus Registry (RELESSER) Clin Exp Rheumatol. 2017;35(6):1047&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">28628467</ArticleId></ArticleIdList></Reference><Reference><Citation>Aggarwal A, Phatak S, Srivastava P, Lawrence A, Agarwal V, Misra R. Outcomes in juvenile onset lupus: single center cohort from a developing country. Lupus. 2018;27(11):1867&#x2013;75. doi: 10.1177/0961203318791046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203318791046</ArticleId><ArticleId IdType="pubmed">30071768</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohamed DF, Aziz ABE-DA, Hassan SA-M, Shedid NH, El-Owaidy RH, Teama MAEM. Juvenile lupus: different clinical and serological presentations compared to adult lupus in Egypt. Egypt Rheumatologist. 2018;40(1):55&#x2013;8. doi: 10.1016/j.ejr.2017.04.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejr.2017.04.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahman HM, Hashim HM, Karam RA. Psychiatric disorders in juvenile systemic lupus erythematosus: prevalence and association with autoantibodies. Middle East Current Psychiatry. 2012;19(1):48&#x2013;55. doi: 10.1097/01.XME.0000407897.01230.45.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.XME.0000407897.01230.45</ArticleId></ArticleIdList></Reference><Reference><Citation>Muscal E, Brey RL. Neurologic manifestations of systemic lupus erythematosus in children and adults. Neurol Clin. 2010;28(1):61&#x2013;73. doi: 10.1016/j.ncl.2009.09.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ncl.2009.09.004</ArticleId><ArticleId IdType="pmc">PMC2981505</ArticleId><ArticleId IdType="pubmed">19932376</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang JC, Xiao R, Mercer-Rosa L, Knight AM, Weiss PF. Child-onset systemic lupus erythematosus is associated with a higher incidence of myopericardial manifestations compared to adult-onset disease. Lupus. 2018;27(13):2146&#x2013;54. doi: 10.1177/0961203318804889.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203318804889</ArticleId><ArticleId IdType="pmc">PMC6207474</ArticleId><ArticleId IdType="pubmed">30318995</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakr A, Eid R, Sarhan A, Hammad A, El-Refaey AM, El-Mougy A, et al. Fifteen years of kidney biopsies in children: a single center in Egypt. Saudi journal of kidney diseases and transplantation: an official publication of the Saudi Center for Organ Transplantation. Saudi Arabia. 2014;25(6):1321&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">25394460</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexopoulos H, Kampylafka EI, Fouka P, Tatouli I, Akrivou S, Politis PK, et al. Anti-aquaporin-4 autoantibodies in systemic lupus erythematosus persist for years and induce astrocytic cytotoxicity but not CNS disease. J Neuroimmunol. 2015;289:8&#x2013;11. doi: 10.1016/j.jneuroim.2015.10.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2015.10.007</ArticleId><ArticleId IdType="pubmed">26616866</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Obaidi M, Saunders D, Brown S, Ramsden L, Martin N, Moraitis E, et al. Evaluation of magnetic resonance imaging abnormalities in juvenile onset neuropsychiatric systemic lupus erythematosus. Clin Rheumatol. 2016;35(10):2449&#x2013;56. doi: 10.1007/s10067-016-3376-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-016-3376-9</ArticleId><ArticleId IdType="pmc">PMC5031744</ArticleId><ArticleId IdType="pubmed">27527090</ArticleId></ArticleIdList></Reference><Reference><Citation>Demirkaya E, Bilginer Y, Aktay-Ayaz N, Yalnizoglu D, Karli-Oguz K, Isikhan V, et al. Neuropsychiatric involvement in juvenile systemic lupus erythematosus. Turk J Pediatr. 2008;50(2):126.</Citation><ArticleIdList><ArticleId IdType="pubmed">18664075</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaky MR, Shaat RM, El-Bassiony SR, Abdel Razek AA, Farag SM. Magnetic resonance imaging (MRI) brain abnormalities of neuropsychiatric systemic lupus erythematosus patients in Mansoura city: relation to disease activity. Egypt Rheumatologist. 2015;37(4):S7&#x2013;S11. doi: 10.1016/j.ejr.2015.09.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejr.2015.09.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Aoki-Yoshino K, Uchihara T, Duyckaerts C, Nakamura A, Hauw J-J, Wakayama Y. Enhanced expression of aquaporin 4 in human brain with inflammatory diseases. Acta Neuropathol. 2005;110(3):281&#x2013;8. doi: 10.1007/s00401-005-1052-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-005-1052-2</ArticleId><ArticleId IdType="pubmed">16133546</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukuda AM, Badaut J. Aquaporin 4: a player in cerebral edema and neuroinflammation. J Neuroinflamm. 2012;9:279. doi: 10.1186/1742-2094-9-279.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-9-279</ArticleId><ArticleId IdType="pmc">PMC3552817</ArticleId><ArticleId IdType="pubmed">23270503</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SH, Kim W, Kook MC, Hong EK, Kim HJ. Central nervous system aquaporin-4 autoimmunity presenting with an isolated cerebral abnormality. Mult Scler. 2012;18(9):1340&#x2013;3. doi: 10.1177/1352458512441271.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1352458512441271</ArticleId><ArticleId IdType="pubmed">22760103</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis AM, Graham TB, Zhu Y, McPheeters ML. Depression and medication nonadherence in childhood-onset systemic lupus erythematosus. Lupus. 2018;27(9):1532&#x2013;41. doi: 10.1177/0961203318779710.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203318779710</ArticleId><ArticleId IdType="pmc">PMC6084794</ArticleId><ArticleId IdType="pubmed">29954282</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>